Levine, Deborah JoSchool of Medicine |
|
|
Director of Inpatient and Outpatient Lung Transplantation, Director of Pulmonary Hypertension Center |
|
| 9/2009 - Present | Associate Professor / Clinical and Director of Inpatient and Outpatient Lung Transplantation, Director of Pulmonary Hypertension Center | University of Texas Health Science Center, Medicine, San Antonio, TX |
| Year | Degree | Discipline | Institution |
| 2003 | Clinical Fellowship | Lung Transplantation/Interventional Pulmonology | UTHSCSA San Antonio , TX |
| 2002 | Clinical Fellowship | Critical Care Medicine | UTHSCSA San Antonio , TX |
| 2001 | Clinical Fellowship | Pulmonary Disease | Good Samaritan/VAMC Phoenix , AZ |
| 1999 | Internship | Internal Medicine | Good Samaritan/VAMC Phoenix , AZ |
| 1996 | MD | Medicine | University of Arizona College of Medicine Tucson , AZ |
| 1992 | MS | Pharmacology/Toxicology | University of Arizona/College of Medicine Tucson , AZ |
| 1991 | BS | Physiology | University of California Davis , CA |
Antibody Mediated Rejection - Lung Transplantation |
Critical Care Medicine- Critical Care Board certification and practice in the medical intensive care unit, transplant intensive care unit and surgical intensive care unit |
Internal Medicine- Boarded in internal medicine |
Interventional Pulmonology- Completed fellowship in interventional pulmonology including 2 week course in Heidelberg Germany |
Lung Transplantation- Lung transplant pulmonologist. Care for all aspects of lung transplant patient: ICU care, donor management, post-lung transplant care in and out of the hospital. |
Organ Donor Management in the ICU- Manage organ donors in the icu prior to procurement. This improves the number of donor numbers so we have increased donor organs for transplant recipients. |
Pulmonary Disease- Pulmonologist involved in clinical, research and teaching at UTHSCSA. |
Pulmonary Hypertension- Medical Director of Pulmonary Hypertension Center: Center has >200 patients I follow regularly. This center is the only one in South Texas and the third biggest center in Texas. |
Journal Article |
| R.R. Hachem, M. Kamoun, M. Budev, M. Askar, A. Vivek, Levine DJ, Pollack MS, Dhillon, K. Schechtman, L.E. Lorriana, L.A. Baxter-Lowe, T. Mohanakumar, D. Tyan, R.D. Yusen. HLA Antibodies After Lung Transplantation: Early results of the HALT Study Journal of Heart and Lung Transplantation 2013 Apr;32(4):S76-S77. |
| Levine DJ, Riley DJ, Jorgensen JH, McClain WD, Tio F, Visvesvara GS, Werner SL. Key diagnostic features of granulomatous interstitial nephritis due to Encephlaitozoon cuniculi in a lung transplant recipient Am J Surg Pathol 2013 Mar;37(3):447-452. |
| Levine DJ, Riley DJ, Jorgensen JH, McClain WD, Tio FO, Visvesvara GS, Abbound-Werner SL. Key diagnostic features of granulomatous interstitial nephritis due to Encephalitozoon cuniculi in a lung transplant recipient Amer. J. Surg. Path 2013 Mar;37:447-452. |
| Burguete SR, Levine SM, Restrepo MI, Angel LF, Levine DJ, Coalson JJ, Peters JI. Lung transplantation for Williams-Campbell syndrome with a probable familial association Respir Care 2012 Sep;57(9):1505-1508. |
| Moote Rebecca, Attridge L. Rebecca, Levine DJ. A Clinical Review of Pulmonary Arterial Hypertension Lung Health Professional 2012 Jan;3(2):10-19. |
| Colman RE, Curtis JR, Nelson JE, Barkley J, Beal A, Edelman J, Efferen L, Hadjiliadis D, Levine DJ, Meyer K, Padilla M, Strek M, Varkey B, Willie K, Singer LG. Barriers to Optimal Palliative Care of Lung Transplant Candidates Chest 2011 Apr;30(4):S28-S28. |
| Levine DJ, Pollack MS, Werner SL, Coalson JJ, Angel LF. Post-transplant donor specific antibodies with or without positive C4d staining are correlated with poor lung transplant outcomes American Transplant Congress Annual Meeting 2009 May;. |
Abstract |
| Levine DJ. coronary artery disease: stress testing, follow-up and referral; 2011 Mar. (Med Health R I; vol. 94, no. 3). |
Other |
| Levine DJ. Lung Health Professional Magazine, Editor Lung Health Professional 2012 Jan;3(2). |
Federal |
|
| Funding Agency | NIH |
| Title | HALT: ANTIBODY MEDIATED REJECTION IN LUNG Transplant R34 NIH Transplant Grant |
| Status | Active |
| Period | 10/2010 - 8/2013 |
| Role | Co-Investigator |
| Grant Detail | co-investigator for site grant number is NHLBI R34 HL105412 no cost extension granted for one year to 8/31/2013 renewal under process |
Private |
|
| Funding Agency | |
| Title | The role of C4D staining and donor specific antibodies in Lung Transplant Rejection: A Retrospective Chart Review to evaluate the role of C4D staining and histologic featurers of transplant trans-bronchial biopsies. |
| Status | Active |
| Period | 5/2008 - Present |
| Role | Principal Investigator |
| Grant Detail | |
| Funding Agency | Emphasys, Inc. |
| Title | Endobronchial Valve for Emphysema Palliation Trial - VENT |
| Status | Active |
| Period | 6/2008 - Present |
| Role | Co-Investigator |
| Grant Detail | Goal: To relieve symptoms and improve quality of life of emphysema patients without surgical intervention Evaluate the safety and efficacy of the Emphasys Endobronchial Valve for Emphysema Palliation Trial (VENT) |
| Funding Agency | United Therapeutics |
| Title | ASPIRE: PAH study - A postmarketing observational study to assess respiratory tract adverse events in pulmonary arterial hypertension pstients treated with Tyvaso (Treprostinil) inhalation solution |
| Status | Active |
| Period | 5/2011 - 1/2029 |
| Role | Co-Principal Investigator |
| Grant Detail | PAH study - A postmarketing observational study to assess respiratory tract adverse events in pulmonary arterial hypertension pstients treated with Tyvaso (Treprostinil) inhalation solution |
| Funding Agency | Spiration Inc. |
| Title | A prospective randomized controlled multicenter clinical trial to evaluate the safety and effectiveness of the IBV valve system for the treatment of severe emphysema. |
| Status | Active |
| Period | 7/2005 - 1/2029 |
| Role | Co-Investigator |
| Grant Detail | |
| Funding Agency | Co Therix Inc |
| Title | Registry to EValuate Early and Long-term Pulmonary Arterial Hypertension Disease Management (REVEAL Registry) |
| Status | Active |
| Period | 11/2010 - 1/2019 |
| Role | Principal Investigator |
| Grant Detail | Total funding amount and receipt dependent on participant enrollment. Approved for up to $187,500. Patients are enrolled and updates are done on a quarterly basis for 5 years. There is an annual meeting nationally for centers involved in this area. |
| Funding Agency | UHN Toronto |
| Title | A Multicenter, Multinational, Retrospective Review of Voriconazole Experience for the Prophylaxis against Invasive Aspergillosis in Lung Transplant Recipients |
| Status | Active |
| Period | 10/2012 - Present |
| Role | Principal Investigator |
| Grant Detail | |